# Silvaco Group, Inc.: financial statements, quarterly

SVCO · Nasdaq · CIK 1943289 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/svco.md) · [Financials](/companies/svco/financials.md) · [Filings](/companies/svco/filings.md) · [Insiders](/companies/svco/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/svco/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [14.9](/filings/0001628280-24-047282.md) | [12.5 d](/filings/0001628280-25-010567.md) | [15.9](/filings/0001628280-25-023248.md) | [15.0](/filings/0001628280-25-038416.md) | [11.0](/filings/0001943289-25-000019.md) | [17.9 d](/filings/0001628280-26-017378.md) | [14.1](/filings/0001628280-26-032286.md) | [12.0](/filings/0001628280-26-054449.md) | [18.7](/filings/0001943289-25-000019.md) | [18.3 d](/filings/0001628280-26-017378.md) | [17.8](/filings/0001628280-26-032286.md) | [17.8](/filings/0001628280-26-054449.md) |
| Cost of revenue | $m | [2.3](/filings/0001628280-24-047282.md) | [2.7 d](/filings/0001628280-25-010567.md) | [2.0](/filings/0001628280-25-023248.md) | [4.9](/filings/0001628280-25-038416.md) | [2.8](/filings/0001943289-25-000019.md) | [2.4 d](/filings/0001628280-26-017378.md) | [3.0](/filings/0001628280-26-032286.md) | [3.5](/filings/0001628280-26-054449.md) | [4.1](/filings/0001943289-25-000019.md) | [3.0 d](/filings/0001628280-26-017378.md) | [2.4](/filings/0001628280-26-032286.md) | [2.6](/filings/0001628280-26-054449.md) |
| Gross profit | $m | [12.7](/filings/0001628280-24-047282.md) | [9.8 d](/filings/0001628280-25-010567.md) | [13.9](/filings/0001628280-25-023248.md) | [10.1](/filings/0001628280-25-038416.md) | [8.2](/filings/0001943289-25-000019.md) | [15.4 d](/filings/0001628280-26-017378.md) | [11.1](/filings/0001628280-26-032286.md) | [8.5](/filings/0001628280-26-054449.md) | [14.5](/filings/0001943289-25-000019.md) | [15.2 d](/filings/0001628280-26-017378.md) | [15.3](/filings/0001628280-26-032286.md) | [15.2](/filings/0001628280-26-054449.md) |
| Research and development | $m | [3.3](/filings/0001628280-24-047282.md) | [3.3 d](/filings/0001628280-25-010567.md) | [3.6](/filings/0001628280-25-023248.md) | [7.7](/filings/0001628280-25-038416.md) | [4.1](/filings/0001943289-25-000019.md) | [5.3 d](/filings/0001628280-26-017378.md) | [4.8](/filings/0001628280-26-032286.md) | [5.9](/filings/0001628280-26-054449.md) | [8.7](/filings/0001943289-25-000019.md) | [10.4 d](/filings/0001628280-26-017378.md) | [9.2](/filings/0001628280-26-032286.md) | [8.8](/filings/0001628280-26-054449.md) |
| Operating income | $m | [1.7](/filings/0001628280-24-047282.md) | [(1.9) d](/filings/0001628280-25-010567.md) | [2.4](/filings/0001628280-25-023248.md) | [(37.8)](/filings/0001628280-25-038416.md) | [(7.3)](/filings/0001943289-25-000019.md) | [2.4 d](/filings/0001628280-26-017378.md) | [(19.6)](/filings/0001628280-26-032286.md) | [(10.1)](/filings/0001628280-26-054449.md) | [(9.3)](/filings/0001943289-25-000019.md) | [(6.8) d](/filings/0001628280-26-017378.md) | [(5.7)](/filings/0001628280-26-032286.md) | [(4.0)](/filings/0001628280-26-054449.md) |
| Interest expense | $m | [(0.0)](/filings/0001628280-24-047282.md) | [0.1 d](/filings/0001628280-25-010567.md) | [0.2](/filings/0001628280-25-023248.md) | [0.3](/filings/0001628280-25-038416.md) | [0.3](/filings/0001628280-24-047282.md) | [0.1 d](/filings/0001628280-25-010567.md) | [0.3](/filings/0001628280-25-023248.md) | [0.4](/filings/0001628280-25-038416.md) | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.3](/filings/0001628280-24-047282.md) | [0.2 d](/filings/0001628280-25-010567.md) | [0.8](/filings/0001628280-25-023248.md) | [0.2](/filings/0001628280-25-038416.md) | [0.2](/filings/0001943289-25-000019.md) | [(0.7) d](/filings/0001628280-26-017378.md) | [0.2](/filings/0001628280-26-032286.md) | [(0.5)](/filings/0001628280-26-054449.md) | [(3.6)](/filings/0001943289-25-000019.md) | [0.5 d](/filings/0001628280-26-017378.md) | [0.1](/filings/0001628280-26-032286.md) | [(0.7)](/filings/0001628280-26-054449.md) |
| Net income | $m | [1.4](/filings/0001628280-24-047282.md) | [(2.2) d](/filings/0001628280-25-010567.md) | [1.4](/filings/0001628280-25-023248.md) | [(38.4)](/filings/0001628280-25-038416.md) | [(6.6)](/filings/0001943289-25-000019.md) | [4.2 d](/filings/0001628280-26-017378.md) | [(19.3)](/filings/0001628280-26-032286.md) | [(9.4)](/filings/0001628280-26-054449.md) | [(5.3)](/filings/0001943289-25-000019.md) | [(7.2) d](/filings/0001628280-26-017378.md) | [(5.9)](/filings/0001628280-26-032286.md) | [(3.7)](/filings/0001628280-26-054449.md) |
| Diluted EPS | $ per share | [0.07](/filings/0001628280-24-047282.md) | not reported | [0.07](/filings/0001628280-25-023248.md) | [(1.55)](/filings/0001628280-25-038416.md) | [(0.23)](/filings/0001943289-25-000019.md) | not reported | [(0.67)](/filings/0001628280-26-032286.md) | [(0.32)](/filings/0001628280-26-054449.md) | [(0.18)](/filings/0001943289-25-000019.md) | not reported | [(0.19)](/filings/0001628280-26-032286.md) | [(0.11)](/filings/0001628280-26-054449.md) |
| Basic EPS | $ per share | [0.07](/filings/0001628280-24-047282.md) | not reported | [0.07](/filings/0001628280-25-023248.md) | [(1.55)](/filings/0001628280-25-038416.md) | [(0.23)](/filings/0001943289-25-000019.md) | not reported | [(0.67)](/filings/0001628280-26-032286.md) | [(0.32)](/filings/0001628280-26-054449.md) | [(0.18)](/filings/0001943289-25-000019.md) | not reported | [(0.19)](/filings/0001628280-26-032286.md) | [(0.11)](/filings/0001628280-26-054449.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [4.4](/filings/0001628280-25-010567.md) | [5.7](/filings/0001628280-24-029005.md) | [34.3](/filings/0001628280-25-038416.md) | [26.6](/filings/0001943289-25-000019.md) | [19.6](/filings/0001628280-26-017378.md) | [29.5](/filings/0001628280-25-023248.md) | [13.1](/filings/0001628280-26-054449.md) | [11.9](/filings/0001943289-25-000019.md) | [9.0](/filings/0001628280-26-054449.md) | [10.9](/filings/0001628280-26-032286.md) | [13.0](/filings/0001628280-26-054449.md) |
| Current assets | $m | not reported | [20.9](/filings/0001628280-25-010567.md) | [24.2](/filings/0001628280-24-029005.md) | [108](/filings/0001628280-24-035713.md) | [119](/filings/0001628280-24-047282.md) | [107](/filings/0001628280-26-017378.md) | [99.9](/filings/0001628280-25-023248.md) | [82.1](/filings/0001628280-25-038416.md) | [53.0](/filings/0001943289-25-000019.md) | [46.1](/filings/0001628280-26-054449.md) | [38.2](/filings/0001628280-26-032286.md) | [43.3](/filings/0001628280-26-054449.md) |
| Total assets | $m | not reported | [40.9](/filings/0001628280-25-010567.md) | [47.4](/filings/0001628280-24-029005.md) | [149](/filings/0001628280-24-035713.md) | [146](/filings/0001628280-24-047282.md) | [142](/filings/0001628280-26-017378.md) | [138](/filings/0001628280-25-023248.md) | [128](/filings/0001628280-25-038416.md) | [131](/filings/0001943289-25-000019.md) | [123](/filings/0001628280-26-054449.md) | [111](/filings/0001628280-26-032286.md) | [115](/filings/0001628280-26-054449.md) |
| Current liabilities | $m | not reported | [25.0](/filings/0001628280-25-010567.md) | [26.2](/filings/0001628280-24-029005.md) | [40.0](/filings/0001628280-24-035713.md) | [40.4](/filings/0001628280-24-047282.md) | [34.5](/filings/0001628280-26-017378.md) | [46.7](/filings/0001628280-25-023248.md) | [38.6](/filings/0001628280-25-038416.md) | [41.8](/filings/0001943289-25-000019.md) | [38.4](/filings/0001628280-26-054449.md) | [27.0](/filings/0001628280-26-032286.md) | [25.2](/filings/0001628280-26-054449.md) |
| Total liabilities | $m | not reported | [31.5](/filings/0001628280-25-010567.md) | [36.8](/filings/0001628280-24-029005.md) | [47.6](/filings/0001628280-24-035713.md) | [47.8](/filings/0001628280-24-047282.md) | [42.3](/filings/0001628280-26-017378.md) | [54.5](/filings/0001628280-25-023248.md) | [48.0](/filings/0001628280-25-038416.md) | [51.5](/filings/0001943289-25-000019.md) | [47.7](/filings/0001628280-26-054449.md) | [34.7](/filings/0001628280-26-032286.md) | [31.6](/filings/0001628280-26-054449.md) |
| Long-term debt | $m | not reported | [0.0](/filings/0001628280-24-029005.md) | [4.3](/filings/0001628280-24-029005.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [11.4](/filings/0001628280-24-047282.md) | [9.4](/filings/0001628280-26-017378.md) | [10.6](/filings/0001628280-25-038416.md) | [102](/filings/0001943289-25-000019.md) | [98.7](/filings/0001943289-25-000019.md) | [100](/filings/0001628280-26-054449.md) | [83.6](/filings/0001628280-26-054449.md) | [79.6](/filings/0001628280-26-054449.md) | [79.1](/filings/0001943289-25-000019.md) | [75.0](/filings/0001628280-26-054449.md) | [76.7](/filings/0001628280-26-054449.md) | [83.6](/filings/0001628280-26-054449.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2023-09-30) | period not labelled (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.8) d](/filings/0001628280-24-047282.md) | [0.8 d](/filings/0001628280-25-010567.md) | [(2.6)](/filings/0001628280-25-023248.md) | [(6.2) d](/filings/0001628280-25-038416.md) | [(1.9) d](/filings/0001943289-25-000019.md) | [(9.1) d](/filings/0001628280-26-017378.md) | [(1.1)](/filings/0001628280-26-032286.md) | [(15.5) d](/filings/0001628280-26-054449.md) | [(7.8) d](/filings/0001943289-25-000019.md) | [(9.5) d](/filings/0001628280-26-017378.md) | [(11.0)](/filings/0001628280-26-032286.md) | [(5.5) d](/filings/0001628280-26-054449.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001628280-24-047282.md) | [0.1 d](/filings/0001628280-25-010567.md) | [0.0](/filings/0001628280-25-023248.md) | [0.0 d](/filings/0001628280-25-038416.md) | [0.3 d](/filings/0001943289-25-000019.md) | [0.2 d](/filings/0001628280-26-017378.md) | [0.1](/filings/0001628280-26-032286.md) | [0.1 d](/filings/0001628280-26-054449.md) | [0.4 d](/filings/0001943289-25-000019.md) | [0.0 d](/filings/0001628280-26-017378.md) | [0.0](/filings/0001628280-26-032286.md) | [0.0 d](/filings/0001628280-26-054449.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2023-03-31) | period not labelled (2023-06-30) | period not labelled (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [20.0](/filings/0001628280-24-029005.md) | [20.0](/filings/0001628280-24-035713.md) | [20.0](/filings/0001628280-24-047282.md) | [20.0](/filings/0001628280-25-023248.md) | [24.8](/filings/0001628280-25-038416.md) | [29.0](/filings/0001943289-25-000019.md) | [28.7](/filings/0001628280-26-032286.md) | [29.3](/filings/0001628280-26-054449.md) | [30.2](/filings/0001943289-25-000019.md) | [31.4](/filings/0001628280-26-032286.md) | [33.0](/filings/0001628280-26-054449.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,885,758 at 2026-08-03, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054449.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.